Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lifecore Biomedical, Inc. \De\ (LFCR) Operating Margin (2016 - 2025)

Historic Operating Margin for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to 14.62%.

  • Lifecore Biomedical, Inc. \De\'s Operating Margin rose 89400.0% to 14.62% in Q2 2025 from the same period last year, while for May 2025 it was 13.38%, marking a year-over-year decrease of 64900.0%. This contributed to the annual value of 13.38% for FY2025, which is 64900.0% down from last year.
  • Per Lifecore Biomedical, Inc. \De\'s latest filing, its Operating Margin stood at 14.62% for Q2 2025, which was up 89400.0% from 25.68% recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s Operating Margin's 5-year high stood at 14.62% during Q2 2025, with a 5-year trough of 46.89% in Q3 2024.
  • Its 5-year average for Operating Margin is 12.51%, with a median of 11.56% in 2022.
  • As far as peak fluctuations go, Lifecore Biomedical, Inc. \De\'s Operating Margin skyrocketed by 278400bps in 2021, and later plummeted by -388900bps in 2022.
  • Lifecore Biomedical, Inc. \De\'s Operating Margin (Quarter) stood at 14.41% in 2021, then plummeted by -270bps to 24.48% in 2022, then soared by 80bps to 4.92% in 2023, then dropped by -22bps to 6.02% in 2024, then soared by 343bps to 14.62% in 2025.
  • Its Operating Margin was 14.62% in Q2 2025, compared to 25.68% in Q1 2025 and 6.02% in Q4 2024.